Trials / Unknown
UnknownNCT03193424
Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
A Prospective, Open-label, Randomized Controlled Clinical Study of Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- The First Affiliated Hospital of Zhengzhou University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Esophageal cancer is a common malignant tumor in china, occupies the second place of malignant tumor morbidity and mortality, the overall 5-year survival rate less than 20%.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2018-12-30
- Completion
- 2019-12-30
- First posted
- 2017-06-20
- Last updated
- 2017-06-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03193424. Inclusion in this directory is not an endorsement.